$OTLK is a biopharmaceutical company focused on the commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases.
Iselin, NJ
Joined June 2020
- Tweets492
- Following119
- Followers1.3K
- Likes49
Pinned Tweet
The FDA has approved LYTENAVA™, the only ophthalmic bevacizumab formulation indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD).
See more at bit.ly/4yGkvX3
#LYTENAVA #Bevacizumab #FDAApproval
#RetinaCare #AMD #Ophthalmology
Stay connected to what’s happening at $OTLK.
Sign up for email alerts to receive the latest company news, regulatory updates and developments from Outlook Therapeutics directly in your inbox.
Subscribe: bit.ly/48ZjFXP
#Ophthalmology #VisionHealth
ICYMI: $OTLK CEO Bob Jahr recently joined Virtual Investor for a CEO Connect segment to highlight recent advancements at Outlook Therapeutics.
Watch here: vimeo.com/1225420337/fcc14a4…
#WetAMD
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
bit.ly/4jNPcVa
$OTLK #Ophthalmology #VisionHealth #EyeHealth
On #WorldSightDay, we recognize the importance of protecting vision and advancing eye care for people around the world.
At $OTLK, our focus on wet AMD reflects our commitment to expanding treatment options for patients facing this sight-threatening retinal disease.
#WetAMD
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
bit.ly/4yEWcbM
$OTLK #Ophthalmology #VisionHealth #EyeHealth
This #BlindnessAwarenessMonth, we recognize the impact vision loss can have on patients and their families.
At $OTLK, we remain committed to advancing care for people living with serious retinal diseases and helping protect the vision that connects us to the world.
#Retinal
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
bit.ly/4e7T7Zf
$OTLK #Ophthalmology #VisionHealth #EyeHealth
$OTLK will attend DOG 2026 hosted by the German Society of Ophthalmology, taking place September 24–27 in Berlin, Germany.
The meeting offers an opportunity to engage with the international ophthalmology community and stay at the forefront of developments in retinal care.
September 23–26 brings the retina community to Los Angeles for the Retina Society Annual Meeting.
Outlook Therapeutics looks forward to being part of the conversations and scientific exchange shaping the future of retinal care.
bit.ly/4xDjFsn
$OTLK #Retinal #WetAMD
Our on-demand fireside chat for the 28th Annual Global Investment Conference is now available!
Access it here: bit.ly/4cXljxt
$OTLK #Ophthalmology #Retinal #VisionHealth
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand. Access the video webcast here: bit.ly/4cXljxt
bit.ly/4rb2n4q
$OTLK #Ophthalmology #VisionHealth #EyeHealth
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
bit.ly/4ilS2Af
$OTLK #Ophthalmology #VisionHealth #EyeHealth
Get the latest from Outlook Therapeutics delivered to you.
Subscribe to email alerts for timely access to corporate announcements, milestones and other important company news.
Sign up: bit.ly/48ZjFXP
$OTLK #Ophthalmology #Retinal #VisionHealth
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
bit.ly/4xpaCvM
$OTLK #RetinaDisease #Ophthalmology #wetAMD
Outlook Therapeutics retweeted
Restoring vision means restoring possibility.
Hear CEO Bob Jahr discuss why this is an exciting time for Outlook Therapeutics and its mission to expand retinal treatment options.
Watch the Virtual Investor Why Now Series: vimeo.com/1221551545/7e3fa72…
@OutlookTx #ClinicalInsights #RetinaResearch #DataUpdates #EyeHealth $OTLK #VirtualInvestor
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Access the webcast here: bit.ly/4zBGZZX
bit.ly/46mzNTU
$OTLK #RetinaDisease #Ophthalmology #wetAMD #VirtualInvestor @InvestorVirtual
Keep an eye on what’s ahead for LYTENAVA™, the only FDA-approved ophthalmic bevacizumab formulation for neovascular (wet) age-related macular degeneration (nAMD).
Sign up at bit.ly/4yGkvX3
#ClinicalInsights #RetinaResearch #DataUpdates #EyeHealth
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
bit.ly/4hEGs2R
$OTLK #RetinaDisease #Ophthalmology #wetAMD
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
bit.ly/4g3OZcZ
$OTLK
